Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development
PR97364
BEIJING, Aug. 8, 2022 /PRNewswire=KYODO JBN/ --
The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in
east China's Jiangsu Province witnessed the launch of Wuxi Intellectual
Property Protection Center with 52 biomedical projects contracted, involving a
total of more than 30 billion yuan investment.
Biomedical industry is an important part of Wuxi's modern industrial system
construction during the 14th Five-Year Plan(2021-2025) period. Its scale topped
140 billion yuan in 2021, a year-on-year increase of 24 percent, making Wuxi
among the top 20 prefecture-level cities listed in China Biomedical Industry
Barometer in 2021.
Besides the property protection center, six biomedical industrial parks were
licensed and three biomedical public platforms were inaugurated at the
conference, which are expected to inject impetus to the development of Wuxi's
biomedical industry.
The city will strengthen and expand its industrial chain to build a
200-billion-yuan modern biomedical industrial cluster, said Du Xiaogang,
Secretary of the Wuxi Municipal Party Committee of CPC.
The biomedical industry started early in Wuxi. With good foundation, it has
developed a relatively comp industry chain covering chemical raw medicine
production, preparation production, and pharmaceutical service outsourcing, and
gathered 1,278 biomedical companies such as AstraZeneca and WuXi Biologics
AppTech, showing strong clustering effect.
Aiming at building a world-class biomedical industry highland with distinctive
characteristics, Wuxi not only issued a special policy tailored for the
development of biomedical industrial parks, but also established a special fund
for modern biomedical industry to reward breakthrough in the forward-looking
technologies and innovation research. In 2021, Wuxi funded more than 32 million
yuan for the science and technology development of 43 biomedical projects.
Multiple fund agreements were signed at the conference, including a biomedical
fund of 5 billion yuan jointly established by Guolian Group, AstraZeneca, and
China International Capital Corporation Limited.
Original link: https://en.imsilkroad.com/p/329376.html
Source Xinhua Silk Road
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=427118
Caption: Photo shows 2022 Taihu Bay Future Healthcare Conference site
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。